Biotechnology company · REGN

Regeneron
clinical trial
pipeline

Registry checked

Published

Cenvacibart is linked to 11 distinct active studies, with 1 Phase 1, 1 Phase 2, 9 Phase 3. Linvoseltamab is linked to 13 distinct active studies, with 2 Phase 1, 6 Phase 2, 4 Phase 3, 1 Phase 4.

Phase 2 study NCT06190951 in Melanoma lists estimated primary completion on 2 November 2026. Phase 2 study NCT04626635 in Advanced Solid Tumors lists estimated primary completion on 13 November 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

125active trials
as lead sponsor
  • Phase 118
  • Phase 253
  • Phase 340
  • Phase 44
  • Phase not recorded10

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

139 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation

NCT07753148 · ClinicalTrials.gov
Recorded by ComplyRx
28 Oct 2026
Registry last updated
27 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000221
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-071000011
2026-10-080100121
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-161010021
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-201010021
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-261000011
2026-10-270000000
2026-10-281000011
2026-10-290000111
2026-10-300000000
2026-10-310000000
Type totals61204139 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Linvoseltamab

Canonical investigational asset

13
Active trials
10
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 12
  • Phase 26
  • Phase 34
  • Phase 41
  • Phase not recorded0
Studied condition
Amyloidosis Stage I-IIIA · Food Allergy · High Risk Smoldering Multiple Myeloma (HR-SMM)
Next primary completion
Not reported
Open drug

Cenvacibart

Canonical investigational asset

11
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 39
  • Phase 40
  • Phase not recorded0
Studied condition
Atrial Fibrillation (AF) · Cancer-Associated Thrombosis (CAT) · Healthy Volunteers
Next primary completion
09 February 2027 · estimated
Open drug

Dupilumab

Dupixent

8
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 21
  • Phase 32
  • Phase 42
  • Phase not recorded3
Studied condition
Asthma · Atopic Dermatitis · Chronic Obstructive Pulmonary Disease (COPD)
Next primary completion
Not reported
Open drug

Cemiplimab

libtayo

8
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 24
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Malignancies · Cutaneous Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma (CSCC)
Next primary completion
20 May 2027 · estimated
Open drug

Odronextamab

Canonical investigational asset

7
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
B-cell Non-Hodgkin Lymphoma (B-NHL) · B-Cell Non-Hodgkin Lymphoma (B-NHL) · B-cell Non-Hodgkins Lymphoma (B-NHL)
Next primary completion
Not reported
Open drug

Fianlimab

Canonical investigational asset

6
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Non-Small Cell Lung Cancer · Melanoma · Non-small Cell Lung Cancer
Next primary completion
22 March 2027 · estimated
Open drug

110 of 125 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 110 of 125 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Regeneron trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Fianlimab/Cemiplimab

NCT06190951

Phase 2 · Active, not recruiting

Trial source and qualifications

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

6 candidate observations · 0 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

6 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 18 Sept 2024 · actual
    Primary completion: 02 Nov 2026 · estimated
    Study completion: 09 Dec 2030 · estimated

    2021202220232024202520262027202820292030
    COMBINE-EGFR-1
    Marlotamig

    NCT04626635

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

    Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    Start clipped at the display horizon.

    4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 21 Dec 2020 · actual
      Primary completion: 13 Nov 2026 · estimated
      Study completion: 05 Mar 2027 · estimated

      2021202220232024202520262027202820292030
      Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
      Olatorepatide

      NCT07431086

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

      3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      3 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 16 Mar 2026 · actual
        Primary completion: 13 Nov 2026 · estimated
        Study completion: 18 Dec 2026 · estimated

        2021202220232024202520262027202820292030
        FERVENT-1
        Exerenibart

        NCT06421636

        Phase 2 · Active, not recruiting

        Trial source and qualifications

        A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

        4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        4 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 30 Sept 2024 · actual
          Primary completion: 03 Dec 2026 · estimated
          Study completion: 03 Dec 2026 · estimated

          2021202220232024202520262027202820292030
          ASCEND-QW
          Alirocumab

          NCT07477704

          Phase 2 · Active, not recruiting

          Trial source and qualifications

          A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

          4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          2 inspected observations omitted. At most three verified observations are shown, not full history.

          • enrollment change · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
          • status flip · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 17 Jun 2026 · actual
          Primary completion: 29 Dec 2026 · estimated
          Study completion: 23 Feb 2027 · estimated

          2021202220232024202520262027202820292030
          ROXI-ATLAS
          Cenvacibart

          NCT07175428

          Phase 2 · Recruiting

          Trial source and qualifications

          Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

          2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          2 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 20 Oct 2025 · actual
            Primary completion: 09 Feb 2027 · estimated
            Study completion: 21 Apr 2027 · estimated

            2021202220232024202520262027202820292030

            Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

            6 selected of 64 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 8 actual primary completions, 0 untyped primary completions, 4 past estimates, 17 outside the horizon, 0 contradictory dates.

            04 / Therapeutic focus

            Where the activity is

            53

            active trials in Oncology

            Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

            Active trials by primary therapeutic area

            • Oncology53 trials
            • Metabolic/Endocrine/Nutrition15 trials
            • Cardiovascular9 trials
            • Immunology & Inflammation7 trials
            • Haematology5 trials
            • Neurology5 trials
            • Dermatology4 trials
            • Renal & Urology3 trials
            • Respiratory3 trials
            • ENT & Hearing2 trials
            • Ophthalmology2 trials
            • Womens Health1 trials
            • Unmapped14 trials
            • Healthy volunteers2 trials

            Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

            06 / Related companies

            All companies
            A

            AbbVie

            Shared indexed programme context · 1 selected asset

            S

            Sanofi

            Shared indexed programme context · 1 selected asset

            Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

            Sources, scope and methodology

            ClinicalTrials.gov lead-sponsor scope

            Canonical current-owner attribution covers 411 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Regeneron Pharmaceuticals. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

            ClinicalTrials.gov

            Attribution coverage

            411 distinct registry candidates produced 411 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

            Indexed enrichment

            379 scoped records have indexed enrichment and 32 do not. Missing enrichment does not remove a trial from cohort counts.

            Scope observation

            The successful attribution check completed at 2026-11-01T02:15:28.381Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 5ae51b7ff3d2bc26aeba7cde0edd5cf80c12aaf231825e8a411daeaa5260c70c.

            Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

            Dated canonical-attribution snapshot: 411 mapped lead-sponsored clinical studies across all statuses. 379 have indexed enrichment, 32 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

            Keep following
            what matters.

            Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

            Build your watch

            Choose what to track in the watch builder.